<p>Arcellx（纳斯达克代码：ACLX - 获取免费报告）在周一发布给投资者的研究报告中被 Truist Financial 的研究分析师升级为 “强力买入” 评级，Zacks.com 报道。</p>
<p>其他几位股票研究分析师最近也对该股票发表了看法。TD Cowen 在 3 月 2 日的报告中将 Arcellx 的评级从 “强力买入” 下调至 “持有”。Guggenheim 在 2 月 25 日的报告中将 Arcellx 的评级从 “买入” 下调至 “中性”，并将其目标价格从 120.00 美元下调至 115.00 美元。Leerink Partners 在 2 月 24 日的研究报告中重申了 “市场表现” 评级，并对 Arcellx 的股票设定了 115.00 美元的目标价格。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Arcellx 的 “卖出（d-）” 评级。最后，William Blair 在 2 月 23 日的研究报告中将 Arcellx 的评级从 “强力买入” 下调至 “持有”。一位股票研究分析师给予该股票 “强力买入” 评级，一位给予 “买入” 评级，十六位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “持有”，共识目标价格为 111.87 美元。</p>
<p><strong>阅读我们关于 Arcellx 的最新报告</strong></p>
<h2>Arcellx 价格表现</h2>
<p>ACLX 股票在周一开盘价为 115.10 美元。Arcellx 的 1 年最低价为 47.86 美元，1 年最高价为 115.13 美元。该股票的 50 日移动平均线为 110.81 美元，200 日移动平均线为 87.46 美元。公司的市值为 67.3 亿美元，市盈率为-28.28，贝塔值为 0.25。</p>
<p>Arcellx（纳斯达克代码：ACLX - 获取免费报告）于 2 月 26 日星期四发布了其季度财报。公司报告每股收益为（1.01 美元），符合分析师的共识预期（1.01 美元）。Arcellx 的净利润率为-1,027.26%，股本回报率为-55.42%。该业务的季度收入为 165 万美元，而分析师预期为 1,340 万美元。分析师预计 Arcellx 在当前年度的每股收益为-2.91。</p>
<h2>内部人士下注</h2>
<p>在其他消息中，内部人士 Rami Elghandour 于 2 月 27 日星期五出售了 89,916 股该股票。该股票以 113.92 美元的平均价格出售，总价值为 10,243,230.72 美元。交易后，内部人士直接持有 276,051 股公司股票，价值约为 31,447,729.92 美元。这代表其持股比例减少了 24.57%。该出售在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站访问。内部人士持有公司 8.35% 的股票。</p>
<h2>对 Arcellx 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近也买卖了 ACLX 的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Arcellx 的持仓增加了 5.1%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 28,753 股公司股票，价值 1,893,000 美元，此前在上个季度又购买了 1,390 股。Empowered Funds LLC 在第一季度购买了 Arcellx 的新股份，价值 1,768,000 美元。Intech Investment Management LLC 在第一季度将其在 Arcellx 的持仓增加了 27.7%。Intech Investment Management LLC 现在拥有 21,967 股公司股票，价值 1,441,000 美元，此前在上个季度又购买了 4,760 股。Prudential Financial Inc.在第二季度将其在 Arcellx 的持仓增加了 49.2%。Prudential Financial Inc.现在拥有 4,900 股公司股票，价值 323,000 美元，此前在上个季度又购买了 1,615 股。最后，挪威银行在第二季度购买了 Arcellx 的新股份，价值 739,000 美元。机构投资者和对冲基金持有公司 96.03% 的股票。</p>
<h2>关于 Arcellx</h2>
<p>（获取免费报告）</p>
<p>Arcellx, Inc（纳斯达克代码：ACLX）是一家临床阶段的生物制药公司，专注于发现、开发和商业化下一代细胞疗法，用于肿瘤和自身免疫疾病。公司的专有 ARC-SparX™平台旨在实现对细胞表面受体激活的精确控制，并提高采用细胞疗法的安全性、有效性和持久性。利用这一技术，Arcellx 对免疫细胞进行工程改造，使其具有可交换的模块化抗原结合域，以针对多种与疾病相关的标记。</p>
<p>公司的产品管线包括多个在血液恶性肿瘤和实体肿瘤领域的全资项目，处于不同的临床前和临床开发阶段。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Arcellx</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Arcellx 吗？</h2>
<p>在你考虑 Arcellx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在购买，以便在更广泛的市场注意到之前……而 Arcellx 并不在名单上。</p>
<p>虽然 Arcellx 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ACLX

<p>Truist Financial 将 Arcellx (NASDAQ:ACLX) 的评级上调至 “强力买入”。其他分析师的看法不一，TD Cowen 将其评级下调至 “持有”，Guggenheim 则下调了其目标股价。该股票开盘价为 115.10 美元，1 年区间为 47.86 至 115.13 美元。Arcellx 报告季度每股亏损为（1.01）美元，未能达到收入预期。内部人士出售了股份，机构投资者持有该股票的 96.03%。Arcellx 专注于开发用于肿瘤学和自身免疫疾病的细胞疗法</p>

<p>Arcellx (NASDAQ:ACLX - Get Free Report) was upgraded by research analysts at Truist Financial to a &#34;strong-buy&#34; rating in a research note issued to investors on Monday,Zacks.com reports.</p>
<div class="lb-trans"><p>Arcellx（纳斯达克代码：ACLX - 获取免费报告）在周一发布给投资者的研究报告中被 Truist Financial 的研究分析师升级为 “强力买入” 评级，Zacks.com 报道。</p>
</div><p>Several other equities research analysts also recently weighed in on the stock. TD Cowen lowered shares of Arcellx from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, March 2nd. Guggenheim lowered Arcellx from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and decreased their price objective for the company from $120.00 to $115.00 in a report on Wednesday, February 25th. Leerink Partners reissued a &#34;market perform&#34; rating and issued a $115.00 price objective on shares of Arcellx in a research report on Tuesday, February 24th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Arcellx in a research note on Monday, April 20th. Finally, William Blair cut Arcellx from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of &#34;Hold&#34; and a consensus price target of $111.87.</p>
<div class="lb-trans"><p>其他几位股票研究分析师最近也对该股票发表了看法。TD Cowen 在 3 月 2 日的报告中将 Arcellx 的评级从 “强力买入” 下调至 “持有”。Guggenheim 在 2 月 25 日的报告中将 Arcellx 的评级从 “买入” 下调至 “中性”，并将其目标价格从 120.00 美元下调至 115.00 美元。Leerink Partners 在 2 月 24 日的研究报告中重申了 “市场表现” 评级，并对 Arcellx 的股票设定了 115.00 美元的目标价格。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Arcellx 的 “卖出（d-）” 评级。最后，William Blair 在 2 月 23 日的研究报告中将 Arcellx 的评级从 “强力买入” 下调至 “持有”。一位股票研究分析师给予该股票 “强力买入” 评级，一位给予 “买入” 评级，十六位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “持有”，共识目标价格为 111.87 美元。</p>
</div><p><strong>Read Our Latest Report on Arcellx</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Arcellx 的最新报告</strong></p>
</div><h2>Arcellx Price Performance</h2>
<div class="lb-trans"><h2>Arcellx 价格表现</h2>
</div><p>Shares of ACLX stock opened at $115.10 on Monday. Arcellx has a 1-year low of $47.86 and a 1-year high of $115.13. The stock's 50-day moving average is $110.81 and its 200 day moving average is $87.46. The company has a market cap of $6.73 billion, a P/E ratio of -28.28 and a beta of 0.25.</p>
<div class="lb-trans"><p>ACLX 股票在周一开盘价为 115.10 美元。Arcellx 的 1 年最低价为 47.86 美元，1 年最高价为 115.13 美元。该股票的 50 日移动平均线为 110.81 美元，200 日移动平均线为 87.46 美元。公司的市值为 67.3 亿美元，市盈率为-28.28，贝塔值为 0.25。</p>
</div><p>Arcellx (NASDAQ:ACLX - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($1.01) earnings per share for the quarter, meeting analysts' consensus estimates of ($1.01). Arcellx had a negative net margin of 1,027.26% and a negative return on equity of 55.42%. The business had revenue of $1.65 million for the quarter, compared to analysts' expectations of $13.40 million. On average, analysts anticipate that Arcellx will post -2.91 EPS for the current year.</p>
<div class="lb-trans"><p>Arcellx（纳斯达克代码：ACLX - 获取免费报告）于 2 月 26 日星期四发布了其季度财报。公司报告每股收益为（1.01 美元），符合分析师的共识预期（1.01 美元）。Arcellx 的净利润率为-1,027.26%，股本回报率为-55.42%。该业务的季度收入为 165 万美元，而分析师预期为 1,340 万美元。分析师预计 Arcellx 在当前年度的每股收益为-2.91。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, insider Rami Elghandour sold 89,916 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $113.92, for a total value of $10,243,230.72. Following the transaction, the insider directly owned 276,051 shares of the company's stock, valued at approximately $31,447,729.92. This represents a 24.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders own 8.35% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Rami Elghandour 于 2 月 27 日星期五出售了 89,916 股该股票。该股票以 113.92 美元的平均价格出售，总价值为 10,243,230.72 美元。交易后，内部人士直接持有 276,051 股公司股票，价值约为 31,447,729.92 美元。这代表其持股比例减少了 24.57%。该出售在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站访问。内部人士持有公司 8.35% 的股票。</p>
</div><h2>Hedge Funds Weigh In On Arcellx</h2>
<div class="lb-trans"><h2>对 Arcellx 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of ACLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Arcellx by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company's stock worth $1,893,000 after buying an additional 1,390 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Arcellx in the 1st quarter valued at $1,768,000. Intech Investment Management LLC boosted its holdings in shares of Arcellx by 27.7% in the 1st quarter. Intech Investment Management LLC now owns 21,967 shares of the company's stock valued at $1,441,000 after acquiring an additional 4,760 shares during the last quarter. Prudential Financial Inc. raised its holdings in shares of Arcellx by 49.2% during the second quarter. Prudential Financial Inc. now owns 4,900 shares of the company's stock worth $323,000 after purchasing an additional 1,615 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Arcellx during the second quarter worth $739,000. Institutional investors and hedge funds own 96.03% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近也买卖了 ACLX 的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Arcellx 的持仓增加了 5.1%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 28,753 股公司股票，价值 1,893,000 美元，此前在上个季度又购买了 1,390 股。Empowered Funds LLC 在第一季度购买了 Arcellx 的新股份，价值 1,768,000 美元。Intech Investment Management LLC 在第一季度将其在 Arcellx 的持仓增加了 27.7%。Intech Investment Management LLC 现在拥有 21,967 股公司股票，价值 1,441,000 美元，此前在上个季度又购买了 4,760 股。Prudential Financial Inc.在第二季度将其在 Arcellx 的持仓增加了 49.2%。Prudential Financial Inc.现在拥有 4,900 股公司股票，价值 323,000 美元，此前在上个季度又购买了 1,615 股。最后，挪威银行在第二季度购买了 Arcellx 的新股份，价值 739,000 美元。机构投资者和对冲基金持有公司 96.03% 的股票。</p>
</div><h2>About Arcellx</h2>
<div class="lb-trans"><h2>关于 Arcellx</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arcellx, Inc NASDAQ: ACLX is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company's proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.</p>
<div class="lb-trans"><p>Arcellx, Inc（纳斯达克代码：ACLX）是一家临床阶段的生物制药公司，专注于发现、开发和商业化下一代细胞疗法，用于肿瘤和自身免疫疾病。公司的专有 ARC-SparX™平台旨在实现对细胞表面受体激活的精确控制，并提高采用细胞疗法的安全性、有效性和持久性。利用这一技术，Arcellx 对免疫细胞进行工程改造，使其具有可交换的模块化抗原结合域，以针对多种与疾病相关的标记。</p>
</div><p>The company's pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>公司的产品管线包括多个在血液恶性肿瘤和实体肿瘤领域的全资项目，处于不同的临床前和临床开发阶段。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Arcellx</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Arcellx</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ACLX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arcellx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Arcellx 吗？</h2>
</div><p>Before you consider Arcellx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Arcellx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在购买，以便在更广泛的市场注意到之前……而 Arcellx 并不在名单上。</p>
</div><p>While Arcellx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arcellx 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Arcellx (NASDAQ:ACLX) Upgraded to Strong-Buy at Truist Financial

Market Beat

Arcellx

Arcellx（纳斯达克代码：ACLX）在 Truist Financial 被上调至强力买入评级